Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin add-on after intravenous thrombolysis for acute ischemic stroke
ISRCTN61644835Phase 4Completed
- Sponsor
- Baguio General Hospital and Medical Center
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of cerebrolysin and tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by Baguio General Hospital and Medical Center. Primary endpoints: Modified Rankin Scale at discharge and Modified Rankin Scale at 3 months. Started May 2024; status: completed.
02
Drugs
cerebrolysintissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ISRCTN61644835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61644835.